Gastroenterology
Volume 138, Issue 2 , Pages 513-521.e6 , February 2010

Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

  • Gary L. Davis

      Affiliations

    • Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Gary L. Davis, MD, Hepatology, 4 Roberts, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, Texas 75246. fax: (214) 820-8168
    • ,
  • Miriam J. Alter

      Affiliations

    • Infectious Disease Epidemiology Program, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Hashem El–Serag

      Affiliations

    • Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
    • ,
  • Thierry Poynard

      Affiliations

    • Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie Liver Center, Paris, France
    • ,
  • Linda W. Jennings

      Affiliations

    • Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas

Received 15 July 2009 ,Accepted 28 September 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Conflicts of interest These authors disclose the following: Dr Davis received research funding from Human Genome Science, Merck, Novartis, Roche, Schering Plough, Tibotec, and Vertex Pharmaceuticals. Dr El-Serag received research funding from Schering-Plough and Bayer. Dr Poynard has a research grant from Schering Plough and equity share in BioPredictive. The remaining authors disclose no conflicts.

 Funding Sponsored by an unrestricted grant from Vertex Pharmaceutical Inc.

PII: S0016-5085(09)01885-X

doi: 10.1053/j.gastro.2009.09.067

Gastroenterology
Volume 138, Issue 2 , Pages 513-521.e6 , February 2010

Article Tools

* Image Usage & Resolution